Literature DB >> 30689600

3D reconstruction of CT scans aid in preoperative planning for sarcomatoid renal cancer: A case report and mini-review.

Petr V Glybochko1, Yuriy G Alyaev1, Sergey B Khokhlachev1, Dmitriy N Fiev1, Evgeniy V Shpot1, Nikolay V Petrovsky1, Deying Zhang2, Alexandra V Proskura1, Maria Yurova1, Ethan Lester Matz3, Xisheng Wang4, Anthony Atala3, Yuanyuan Zhang3, Denis V Butnaru1.   

Abstract

Contrast-enhanced multi-slice computed tomography (MSCT) is commonly used in the diagnosis of complex malignant tumours. This technology provides comprehensive and accurate information about tumour size and shape in relation to solid tumours and the affected adjacent organs and tissues. This case report demonstrates the benefit of using MSCT 3D imaging for preoperative planning in a patient with late-stage (T4) sarcomatoid renal cell carcinoma, a rare renal malignant tumour. The surgical margin on the liver was negative, and no metastases to veins, lungs or other organs were detected by abdominal and chest contrast-enhanced CT. Although sarcomatoid histology is considered to be a poor prognostic factor, the patient is alive and well 17 months after surgery. The MSCT imaging modality enables 3D rendering of an area of interest, which assists surgical decision-making in cases of advanced renal tumours. In this case, as a result of MSCT 3D reconstruction, the patient received justified surgical treatment without compromising oncological principles.

Entities:  

Keywords:  Three-dimensional reconstruction; advanced kidney cancer; decision-making; multi-slice computed tomography; renal cell carcinoma; sarcomatoid carcinoma

Mesh:

Year:  2019        PMID: 30689600     DOI: 10.3233/XST-180387

Source DB:  PubMed          Journal:  J Xray Sci Technol        ISSN: 0895-3996            Impact factor:   1.535


  1 in total

1.  The Application Value of CT Three-Dimensional Microscope Reconstruction Technology in the Diagnosis of Cervical Cancer.

Authors:  Shaoliang Sun; Xiye Wang; Yanjia Chen
Journal:  Scanning       Date:  2022-06-06       Impact factor: 1.750

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.